benzonidazole (benznidazole)

06/01/2011 - "We have tested the antiparasital activity in vitro and in vivo of the three new complexes against Trypanosoma cruzi showing very promising results and overcoming clearly the reference drug commonly used for the Chagas disease treatment, benznidazole."
05/16/2006 - "Benznidazole is effective for treating acute-stage Chagas disease, but its effectiveness for treating indeterminate and chronic stages remains uncertain. "
01/01/2015 - "Benznidazole (BNZ) is safe and effective for the treatment of paediatric Chagas disease. "
10/15/2015 - "The current treatment of Chagas disease, endemic in Latin America and emerging in several countries, is limited by the frequent side effects and variable efficacy of benznidazole. "
07/01/2008 - "The goals of this study were to evaluate the efficacy of benznidazole (Bz) treatment in decreasing of the parasitic load during the acute phase of experimental Chagas disease and to analyze its influence in the development of cardiac chronic alterations in mice inoculated with drug-resistant Trypanosoma cruzi strains. "

12/01/2000 - "The antiparasitic drug, benznidazole, is effective when given for the initial infection and may also be beneficial for the chronic phase. "
02/01/2013 - "Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi."
11/23/1996 - "Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection."
01/01/2014 - "In animals with the Y strain treated 24 h after infection for 10 days, only mice treated by LYC-PCL NC were cured, but animals treated in the prepatent period for 20 days exhibited 100, 75, and 62.5% cure when treated with LYC-PLA-PEG NC, benznidazole, and LYC-PCL NC, respectively. "
01/01/2014 - "Animals infected with the CL strain, treated 24 h after infection for 10 days, evaluated by hemoculture, PCR, and enzyme-linked immunosorbent assay exhibited a 50% parasitological cure when treated with LYC-PCL NC and 100% cure when treated with benznidazole, but 100% of the animals treated during the prepatent period for 20 days with these formulations or LYC-PLA-PEG NC were cured. "

09/01/2005 - "The patient was put on benznidazole with rapid clearance of the parasitemia. "
11/01/1998 - "Treatment with benznidazole was effective in reducing parasitemia, stabilizing the clinical status, and controlling tissue damage related to the parasite. "
01/01/1998 - "Specific antitrypanosomal treatment with benznidazole was effective in reducing the level of parasitemia and improving the clinical condition in three of the four patients treated."
01/01/2014 - "LYC-loaded NC showed higher cure rates, reduced parasitemia, and increased survival when used in doses 2five times lower than those used for benznidazole. "
01/01/2014 - "Thiazolidinone 4 h was able to reduce the in vitro parasite burden and the blood parasitemia in mice with similar potency to benznidazole. "

10/01/2012 - "There was a significant reduction of inflammation in skeletal muscles after benznidazole treatment in animals infected with Mexican T. "
10/01/2012 - "We analyzed the intensity of inflammation and parasitism in BALB/c mice infected with Trypanosoma cruzi I stocks from Mexico with and without benznidazole treatment in the acute phase of disease. "
10/01/2012 - "Decreased intensity of inflammation in benznidazole-treated mice inoculated with Trypanosoma cruzi I stocks from Mexico and persistence of circulating parasites."
09/01/2008 - "Although it did not display higher efficacy than benznidazole, DB1362 reduced both cardiac parasitism and inflammation, and in addition, it protected against the cardiac alterations (determined by measurements) common in T. "
05/01/2014 - "H2bdtc encapsulated into solid lipid nanoparticles (a) effectively reduced parasitemia in mice at concentrations 100 times lower than that normally employed for benznidazole (clinically applied at a concentration of 400 µmol kg(-1) day(-1)); (b) diminished inflammation and lesions of the liver and heart; and (c) resulted in 100% survival of mice infected with T. "

08/01/2010 - "The results of the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT) trial in 2012 will also help to inform treatment. "
10/01/2014 - "cruzi, and developed cerebral trypanosomiasis that was successfully treated with benznidazole at 7 mg/kg/day for 60 days. "
01/01/2013 - "The Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) study is an international, multicenter, randomized, double-blinded and placebo-controlled clinical trial to evaluate the efficacy of benznidazole (BZ) treatment in patients with chronic Chagas cardiomyopathy (CCC). "
07/01/2009 - "The BENEFIT project--Benznidazole Evaluation for Interrupting Trypanosomiasis--is an international, multicenter, double-blind, placebo-controlled trial of trypanocidal treatment with benznidazole in patients with chronic Chagas heart disease. "
07/01/2008 - "Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)."